Skip to main content
Erschienen in: Medical Oncology 9/2014

01.09.2014 | Original Paper

Single-strand conformational polymorphism analysis of a common single nucleotide variation in WRAP53 gene, rs2287499, and evaluating its association in relation to breast cancer risk and prognosis among Iranian-Azeri population

verfasst von: Aida Sedaie Bonab, Nasser Pouladi, Mohammad Ali Hosseinpourfeizi, Reyhaneh Ravanbakhsh Gavgani, Roghayeh Dehghan, Parvin Azarfam, Vahid Montazeri, Ashraf Fakhrjou

Erschienen in: Medical Oncology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

The WRAP53 (WD40-encoding RNA antisense to p53) gene encodes an antisense RNA, essential for p53 stabilization and induction upon DNA damage. Single nucleotide polymorphisms (SNPs) in WRAP53 have been associated with risk of cancer, which strengthens the role of WRAP53 in the pathogenesis of human malignancies. In fact, WRAP53 has been considered as a candidate cancer susceptibility gene. Accordingly, we performed a study to examine the association of a frequent genetic variation in WRAP53, rs2287499 (C/G), with breast cancer risk and prognosis among Iranian-Azeri population. A case–control association study, including 206 cases and 203 controls from Iranian-Azeri population, was conducted. Genomic DNA was extracted from peripheral blood and tumor samples by salting-out method. SNP genotyping was carried out by polymerase chain reaction-based single-strand conformational polymorphism (PCR-SSCP) technique. The sequence variation of SSCP banding patterns was determined by sequencing. The collected data were analyzed through statistical package for the social sciences software, using Chi-square (χ 2) or Fisher’s exact tests, with a significance level of 0.05. No significant differences in the allele and genotype frequencies between cases and controls were detected. Similarly, no significant associations between genotypes and clinicopathological data were observed. Concisely, no significant overall associations between rs2287499 and breast cancer risk and prognosis were detected in the studied population. The rs2287499 SNP is not associated with breast cancer predisposition in Iranian-Azeri women; it also cannot be used as a molecular biomarker to predict breast cancer prognosis in Iranian-Azeri population.
Fußnoten
1
Tumor protein p53.
 
2
WD repeat domain 79.
 
3
Telomerase Cajal body protein 1.
 
4
The national center for biotechnology information.
 
Literatur
1.
Zurück zum Zitat Veeramachaneni V, Makałowski W, Galdzicki M, Sood R, Mammalian Makałowska I. Overlapping genes: the comparative perspective. Genome Res. 2004;14(2):280–6.PubMedCrossRefPubMedCentral Veeramachaneni V, Makałowski W, Galdzicki M, Sood R, Mammalian Makałowska I. Overlapping genes: the comparative perspective. Genome Res. 2004;14(2):280–6.PubMedCrossRefPubMedCentral
2.
Zurück zum Zitat Chen J, Sun M, Kent WJ, Huang X, Xie H, Wang W, et al. Over 20 % of human transcripts might form sense–antisense pairs. Nucleic Acids Res. 2004;32(16):4812–20.PubMedCrossRefPubMedCentral Chen J, Sun M, Kent WJ, Huang X, Xie H, Wang W, et al. Over 20 % of human transcripts might form sense–antisense pairs. Nucleic Acids Res. 2004;32(16):4812–20.PubMedCrossRefPubMedCentral
3.
Zurück zum Zitat Mahmoudi S, Henriksson S, Corcoran M, Méndez-Vidal C, Wiman KG, Farnebo M. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell. 2009;33(4):462–71.PubMedCrossRef Mahmoudi S, Henriksson S, Corcoran M, Méndez-Vidal C, Wiman KG, Farnebo M. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell. 2009;33(4):462–71.PubMedCrossRef
5.
Zurück zum Zitat Matera AG, Terns RM, Terns MP. Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. Nat Rev Mol Cell Biol. 2007;8(3):209–20.PubMedCrossRef Matera AG, Terns RM, Terns MP. Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. Nat Rev Mol Cell Biol. 2007;8(3):209–20.PubMedCrossRef
6.
Zurück zum Zitat Mahmoudi S, Henriksson S, Farnebo L, Roberg K, Farnebo M. WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. Cell Death Dis. 2011;2:e114.PubMedCrossRefPubMedCentral Mahmoudi S, Henriksson S, Farnebo L, Roberg K, Farnebo M. WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. Cell Death Dis. 2011;2:e114.PubMedCrossRefPubMedCentral
7.
Zurück zum Zitat Venteicher AS, Abreu EB, Meng Z, McCann KE, Terns RM, Veenstra TD, et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science. 2009;323(5914):644–8.PubMedCrossRefPubMedCentral Venteicher AS, Abreu EB, Meng Z, McCann KE, Terns RM, Veenstra TD, et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science. 2009;323(5914):644–8.PubMedCrossRefPubMedCentral
8.
Zurück zum Zitat Loveday RL, Greenman J, Drew PJ, Monson JR, Kerin MJ. Genetic changes associated with telomerase activity in breast cancer. Int J Cancer. 1999;84(5):516–20.PubMedCrossRef Loveday RL, Greenman J, Drew PJ, Monson JR, Kerin MJ. Genetic changes associated with telomerase activity in breast cancer. Int J Cancer. 1999;84(5):516–20.PubMedCrossRef
9.
Zurück zum Zitat Zhang Y, Eberhard DA, Frantz GD, Dowd P, Wu TD, Zhou Y, et al. GEPIS-quantitative gene expression profiling in normal and cancer tissues. Bioinformatics. 2004;20(15):2390–8.PubMedCrossRef Zhang Y, Eberhard DA, Frantz GD, Dowd P, Wu TD, Zhou Y, et al. GEPIS-quantitative gene expression profiling in normal and cancer tissues. Bioinformatics. 2004;20(15):2390–8.PubMedCrossRef
10.
Zurück zum Zitat Velázquez-Fernández D, Laurell C, Saqui-Salces M, Pantoja JP, Candanedo-Gonzalez F, Reza-Albarrán A. et al: Differential RNA expression profile by cDNA microarray in sporadic primary hyperparathyroidism (pHPT): primary parathyroid hyperplasia versus adenoma. World J Surg. 2006;30(5):705–13.PubMedCrossRef Velázquez-Fernández D, Laurell C, Saqui-Salces M, Pantoja JP, Candanedo-Gonzalez F, Reza-Albarrán A. et al: Differential RNA expression profile by cDNA microarray in sporadic primary hyperparathyroidism (pHPT): primary parathyroid hyperplasia versus adenoma. World J Surg. 2006;30(5):705–13.PubMedCrossRef
11.
Zurück zum Zitat Garcia-Closas M, Kristensen V, Langerød A, Qi Y, Yeager M, Burdett L, et al. Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer. 2007;121(11):2532–8.PubMedCrossRef Garcia-Closas M, Kristensen V, Langerød A, Qi Y, Yeager M, Burdett L, et al. Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer. 2007;121(11):2532–8.PubMedCrossRef
12.
Zurück zum Zitat Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009;69(6):2349–57.PubMedCrossRefPubMedCentral Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009;69(6):2349–57.PubMedCrossRefPubMedCentral
13.
Zurück zum Zitat Zhang H, Wang D-W, Adell G, Sun X-F. WRAP53 is an independent prognostic factor in rectal cancer: a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients. BMC Cancer. 2012;12:294.PubMedCrossRefPubMedCentral Zhang H, Wang D-W, Adell G, Sun X-F. WRAP53 is an independent prognostic factor in rectal cancer: a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients. BMC Cancer. 2012;12:294.PubMedCrossRefPubMedCentral
14.
Zurück zum Zitat Mędrek K, Magnowski P, Masojć B, Chudecka-Głaz A, Torbe B, Menkiszak J, et al. Association of common WRAP53 variant with ovarian cancer risk in the Polish population. Mol Biol Rep. 2013;40(3):2145–7.PubMedCrossRefPubMedCentral Mędrek K, Magnowski P, Masojć B, Chudecka-Głaz A, Torbe B, Menkiszak J, et al. Association of common WRAP53 variant with ovarian cancer risk in the Polish population. Mol Biol Rep. 2013;40(3):2145–7.PubMedCrossRefPubMedCentral
15.
Zurück zum Zitat Rao X, Huang D, Sui X, Liu G, Song X, Xie J, et al. Overexpression of WRAP53 is associated with development and progression of esophageal squamous cell carcinoma. PLoS One. 2014;9(3):91670–9167.CrossRef Rao X, Huang D, Sui X, Liu G, Song X, Xie J, et al. Overexpression of WRAP53 is associated with development and progression of esophageal squamous cell carcinoma. PLoS One. 2014;9(3):91670–9167.CrossRef
16.
Zurück zum Zitat Alonso S, Izagirre N, López S, Smith-Zubiaga I, Hervella M, Boyano MD, et al. The diversity profile of TP53 is influenced by positive selection on the immediately upstream locus WDR79. Hum Hered. 2010;69(1):34–44.PubMedCrossRef Alonso S, Izagirre N, López S, Smith-Zubiaga I, Hervella M, Boyano MD, et al. The diversity profile of TP53 is influenced by positive selection on the immediately upstream locus WDR79. Hum Hered. 2010;69(1):34–44.PubMedCrossRef
17.
Zurück zum Zitat Hashemzadeh S, Aligholipour Maleki R, Golzari SE. The incidence of breast cancer in northwest Iran (2003–2008). J Cardiovasc Thorac Res. 2012;4(1):5–9.PubMedPubMedCentral Hashemzadeh S, Aligholipour Maleki R, Golzari SE. The incidence of breast cancer in northwest Iran (2003–2008). J Cardiovasc Thorac Res. 2012;4(1):5–9.PubMedPubMedCentral
18.
Zurück zum Zitat Akbari ME. Iran cancer report. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran: Darolfekr; 2008. Akbari ME. Iran cancer report. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran: Darolfekr; 2008.
19.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. Breast. In: AJCC cancer staging manual. 7th edn. New York: Springer; 2010. p. 347–76. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. Breast. In: AJCC cancer staging manual. 7th edn. New York: Springer; 2010. p. 347–76.
20.
Zurück zum Zitat Bartlett JMS, editor. Ovarian cancer: methods and protocols. New Jersey: Springer; 2000. p. 262–300. Bartlett JMS, editor. Ovarian cancer: methods and protocols. New Jersey: Springer; 2000. p. 262–300.
21.
Zurück zum Zitat Dong Y, Zhu H. Single-strand conformational polymorphism analysis: basic principles and routine practice. Methods Mol Med. 2005;108:149–57.PubMed Dong Y, Zhu H. Single-strand conformational polymorphism analysis: basic principles and routine practice. Methods Mol Med. 2005;108:149–57.PubMed
22.
Zurück zum Zitat Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; 2001. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; 2001.
23.
Zurück zum Zitat Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, et al. Antisense transcription in the mammalian transcriptome. Science. 2005;309(5740):1564–6.PubMedCrossRef Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, et al. Antisense transcription in the mammalian transcriptome. Science. 2005;309(5740):1564–6.PubMedCrossRef
24.
Zurück zum Zitat Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. Nat Rev Genet. 2013;14(12):880–93.PubMedCrossRef Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. Nat Rev Genet. 2013;14(12):880–93.PubMedCrossRef
25.
Zurück zum Zitat Beiter T, Reich E, Williams RW, Simon P. Antisense transcription: a critical look in both directions. Cell Mol Life Sci. 2009;66(1):94–112.PubMedCrossRef Beiter T, Reich E, Williams RW, Simon P. Antisense transcription: a critical look in both directions. Cell Mol Life Sci. 2009;66(1):94–112.PubMedCrossRef
26.
Zurück zum Zitat Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ. 2006;13(6):1027–36.PubMedCrossRef Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ. 2006;13(6):1027–36.PubMedCrossRef
27.
Zurück zum Zitat Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res. 1999;431(2):199–209.PubMedCrossRef Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res. 1999;431(2):199–209.PubMedCrossRef
28.
Zurück zum Zitat Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 2005;120(1):7–10.PubMed Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 2005;120(1):7–10.PubMed
29.
Zurück zum Zitat Klinken SP, Holmes KL, Morse HC, Thorgeirsson SS. Transcriptional and post-transcriptional regulation of c-myc, c-myb and p53 during proliferation and differentiation of murine erythroleukemia cells treated with DFMO and DMSO. Exp Cell Res. 1988;178(2):185–98.PubMedCrossRef Klinken SP, Holmes KL, Morse HC, Thorgeirsson SS. Transcriptional and post-transcriptional regulation of c-myc, c-myb and p53 during proliferation and differentiation of murine erythroleukemia cells treated with DFMO and DMSO. Exp Cell Res. 1988;178(2):185–98.PubMedCrossRef
30.
Zurück zum Zitat Kim H, You S, Farris J, Foster LK, Foster DN. Post-transcriptional inactivation of p53 in immortalized murine embryo fibroblast cells. Oncogene. 2001;20(25):3306–10.PubMedCrossRef Kim H, You S, Farris J, Foster LK, Foster DN. Post-transcriptional inactivation of p53 in immortalized murine embryo fibroblast cells. Oncogene. 2001;20(25):3306–10.PubMedCrossRef
31.
Zurück zum Zitat Chen J, Sun M, Hurst LD, Carmichael GG, Rowley JD. Genome-wide analysis of coordinate expression and evolution of human cis-encoded sense–antisense transcripts. Trends Genet. 2005;21(6):326–9.PubMedCrossRef Chen J, Sun M, Hurst LD, Carmichael GG, Rowley JD. Genome-wide analysis of coordinate expression and evolution of human cis-encoded sense–antisense transcripts. Trends Genet. 2005;21(6):326–9.PubMedCrossRef
Metadaten
Titel
Single-strand conformational polymorphism analysis of a common single nucleotide variation in WRAP53 gene, rs2287499, and evaluating its association in relation to breast cancer risk and prognosis among Iranian-Azeri population
verfasst von
Aida Sedaie Bonab
Nasser Pouladi
Mohammad Ali Hosseinpourfeizi
Reyhaneh Ravanbakhsh Gavgani
Roghayeh Dehghan
Parvin Azarfam
Vahid Montazeri
Ashraf Fakhrjou
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 9/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0168-4

Weitere Artikel der Ausgabe 9/2014

Medical Oncology 9/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.